Triple therapy takes on aggressive blood cancer

NCT ID NCT05672173

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding a personalized cell therapy (liso-cel) to two existing drugs (nivolumab and ibrutinib) can help people with Richter's transformation, a rare and aggressive blood cancer. The study plans to enroll 9 participants and will measure how many achieve a complete response. It is still early, so the main goals are to check safety and see if the combination is promising enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lisocabtagene maraleucel (a CAR T-cell therapy made from the patient's own immune cells), nivolumab (an immunotherapy drug), and ibrutinib (a targeted cancer pill)
What this could lead to: If this combination works, it could offer a new treatment option for people with Richter's transformation, a very aggressive blood cancer.
What could go wrong: This is a very small, early-phase trial with only 9 participants, so results may not apply to everyone. The combination therapy also carries risks of serious side effects, including immune system overreactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA RICHTER SYNDROME

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.